UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
|
ý |
|
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
|
|
|
|
|
For the period ended March 31, 2004 |
||
|
|
|
|
|
Or |
||
|
|
|
|
|
o |
|
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
|
|
|
|
|
For the transition period from to . |
||
Commission File No. 000-24537
DYAX CORP.
(Exact Name of Registrant as Specified in its Charter)
|
DELAWARE |
|
04-3053198 |
|
(State of Incorporation) |
|
(I.R.S. Employer Identification Number) |
300 TECHNOLOGY SQUARE, CAMBRIDGE, MA 02139
(Address of Principal Executive Offices)
(617) 225-2500
(Registrant’s Telephone Number, including Area Code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
YES ý NO o
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).
YES ý NO o
Number of shares outstanding of Dyax Corp.’s Common Stock, par value $0.01, as of April 30, 2004: 31,165,321.
DYAX CORP.
TABLE OF CONTENTS
2
PART I – FINANCIAL INFORMATION
Dyax Corp. and Subsidiaries Consolidated Balance Sheets (Unaudited)
|
|
|
March 31, |
|
December
31, |
|
||
|
ASSETS |
|
|
|
|
|
||
|
Current assets: |
|
|
|
|
|
||
|
Cash and cash equivalents |
|
$ |
39,399,000 |
|
$ |
36,508,000 |
|
|
Short term investments |
|
34,326,000 |
|
— |
|
||
|
Accounts receivable, net of allowances for doubtful accounts of $98,000 at March 31, 2004 and $75,000 at December 31, 2003 |
|
2,275,000 |
|
4,683,000 |
|
||
|
Cash in escrow |
|
5,000,000 |
|
5,000,000 |
|
||
|
Prepaid research and development |
|
2,040,000 |
|
2,568,000 |
|
||
|
Other current assets |
|
705,000 |
|
586,000 |
|
||
|
|
|
|
|
|
|
||
|
Total current assets |
|
83,745,000 |
|
49,345,000 |
|
||
|
|
|
|
|
|
|
||
|
Fixed assets, net |
|
10,585,000 |
|
10,793,000 |
|
||
|
Intangibles, net |
|
2,792,000 |
|
2,917,000 |
|
||
|
Restricted cash |
|
5,202,000 |
|
5,213,000 |
|
||
|
Investment in joint venture (Kallikrein LLC) |
|
1,745,000 |
|
817,000 |
|
||
|
Other assets |
|
201,000 |
|
201,000 |
|
||
|
|
|
|
|
|
|
||
|
Total assets |
|
$ |
104,270,000 |
|
$ |
69,286,000 |
|
|
|
|
|
|
|
|
||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
||
|
Current liabilities: |
|
|
|
|
|
||
|
Accounts payable and accrued expenses |
|
$ |
11,343,000 |
|
$ |
12,329,000 |
|
|
Current portion of deferred revenue |
|
4,451,000 |
|
6,149,000 |
|
||
|
Current portion of long-term obligations |
|
3,111,000 |
|
3,413,000 |
|
||
|
|
|
|
|
|
|
||
|
Total current liabilities |
|
18,905,000 |
|
21,891,000 |
|
||
|
|
|
|
|
|
|
||
|
Deferred revenue |
|
1,628,000 |
|
1,524,000 |
|
||
|
Obligation to related party |
|
7,000,000 |
|
7,000,000 |
|
||
|
Long-term obligations |
|
3,265,000 |
|
3,648,000 |
|
||
|
Other long-term liabilities |
|
1,257,000 |
|
1,278,000 |
|
||
|
|
|
|
|
|
|
||
|
Total liabilities |
|
32,055,000 |
|
35,341,000 |
|
||
|
|
|
|
|
|
|
||
|
Commitments and Contingencies (Notes 8 and 9) |
|
|
|
|
|
||
|
|
|
|
|
|
|
||
|
Stockholders’ equity: |
|
|
|
|
|
||
|
Preferred stock, $0.01 par value; 1,000,000 shares authorized at March 31, 2004 and December 31, 2003; 0 shares issued and outstanding at March 31, 2004 and December 31, 2003 |
|
— |
|
— |
|
||
|
Common stock, $0.01 par value; 50,000,000 shares authorized at March 31, 2004 and December 31, 2003; 31,134,433 and 24,887,757 shares issued and outstanding at March 31, 2004 and December 31, 2003, respectively |
|
311,000 |
|
249,000 |
|
||
|
Additional paid-in capital |
|
197,049,000 |
|
151,445,000 |
|
||
|
Accumulated deficit |
|
(125,677,000 |
) |
(118,242,000 |
) |
||
|
Deferred compensation |
|
(13,000 |
) |
(47,000 |
) |
||
|
Accumulated other comprehensive income |
|
545,000 |
|
540,000 |
|
||
|
|
|
|
|
|
|
||
|
Total stockholders’ equity |
|
72,215,000 |
|
33,945,000 |
|
||
|
|
|
|
|
|
|
||
|
Total liabilities and stockholders’ equity |
|
$ |
104,270,000 |
|
$ |
69,286,000 |
|
The accompanying notes are an integral part of the unaudited consolidated financial statements.
3
Dyax Corp. and Subsidiaries Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
|
|
|
Three Months Ended March 31, |
|
||||
|
|
|
2004 |
|
2003 |
|
||
|
Product development and license fee revenues |
|
$ |
5,697,000 |
|
$ |
3,856,000 |
|
|
|
|
|
|
|
|
||
|
Research and development: |
|
|
|
|
|
||
|
Research and development |
|
10,332,000 |
|
6,666,000 |
|
||
|
Less research and development expenses reimbursed by joint venture (Kallikrein LLC) |
|
(1,510,000 |
) |
— |
|
||
|
|
|
|
|
|
|
||
|
Net research and development |
|
8,822,000 |
|
6,666,000 |
|
||
|
|
|
|
|
|
|
||
|
Equity loss in joint venture (Kallikrein LLC) |
|
882,000 |
|
— |
|
||
|
|
|
|
|
|
|
||
|
General and administrative |
|
3,275,000 |
|
2,732,000 |
|
||
|
|
|
|
|
|
|
||
|
Total operating expenses |
|
12,979,000 |
|
9,398,000 |
|
||
|
|
|
|
|
|
|
||
|
Loss from operations |
|
(7,282,000 |
) |
(5,542,000 |
) |
||
|
|
|
|
|
|
|
||
|
Other income (expense): |
|
|
|
|
|
||
|
Interest income |
|
130,000 |
|
84,000 |
|
||
|
Interest expense |
|
(283,000 |
) |
(337,000 |
) |
||
|
Total other expense |
|
(153,000 |
) |
(253,000 |
) |
||
|
|
|
|
|
|
|
||
|
Loss from continuing operations |
|
(7,435,000 |
) |
(5,795,000 |
) |
||
|
|
|
|
|
|
|
||
|
Loss from discontinued operations of Biotage, net of tax |
|
— |
|
(584,000 |
) |
||
|
|
|
|
|
|
|
||
|
Net loss |
|
(7,435,000 |
) |
(6,379,000 |
) |
||
|
|
|
|
|
|
|
||
|
Other comprehensive income: |
|
|
|
|
|
||
|
Foreign currency translation adjustments |
|
(9,000 |
) |
— |
|
||
|
Unrealized gain on short term investments |
|
14,000 |
|
— |
|
||
|
Comprehensive loss |
|
$ |
(7,430,000 |
) |
$ |
(6,379,000 |
) |
|
|
|
|
|
|
|
||
|
Basic and diluted loss per share: |
|
|
|
|
|
||
|
Loss from continuing operations |
|
$ |
(0.24 |
) |
$ |
(0.28 |
) |
|
Loss from discontinued operations of Biotage |
|
— |
|
(0.03 |
) |
||
|
Net loss |
|
$ |
(0.24 |
) |
$ |
(0.31 |
) |
|
Shares used in computing basic and diluted net loss per share |
|
30,641,476 |
|
20,378,534 |
|
||
The accompanying notes are an integral part of the unaudited consolidated financial statements.
4
Dyax Corp. and Subsidiaries Consolidated Statements of Cash Flows (Unaudited)
|
|
|
Three Months Ended March 31, |
|
||||
|
|
|
2004 |
|
2003 |
|
||
|
Cash flows from operating activities: |
|
|
|
|
|
||
|
Loss from continuing operations |
|
$ |
(7,435,000 |
) |
$ |
(5,795,000 |
) |
|
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities: |
|
|
|
|
|
||
|
Depreciation and amortization of fixed assets |
|
781,000 |
|
769,000 |
|
||
|
Amortization of intangibles |
|
125,000 |
|
125,000 |
|
||
|
Compensation expenses associated with stock options |
|
40,000 |
|
140,000 |
|
||
|
Equity loss in joint venture (Kallikrein LLC) |
|
882,000 |
|
— |
|
||
|
Provision for doubtful accounts |
|
23,000 |
|
— |
|
||
|
Changes in operating assets and liabilities, net of divestiture |
|
|
|
|
|
||
|
Accounts receivable |
|
2,385,000 |
|
474,000 |
|
||
|
Prepaid research and development, and other assets |
|
574,000 |
|
(205,000 |
) |
||
|
Accounts payable and accrued expenses |
|
(957,000 |
) |
1,071,000 |
|
||
|
Deferred revenue |
|
(1,594,000 |
) |
(110,000 |
) |
||
|
Other long-term liabilities |
|
(7,000 |
) |
145,000 |
|
||
|
Net cash used in operating activities |
|
(5,183,000 |
) |
(3,386,000 |
) |
||
|
|
|
|
|
|
|
||
|
Cash flows from investing activities: |
|
|
|
|
|
||
|
Purchase of fixed assets |
|
(358,000 |
) |
(177,000 |
) |
||
|
Purchase of short term investments |
|
(34,483,000 |
) |
— |
|
||
|
Restricted cash |
|
— |
|
(147,000 |
) |
||
|
Notes receivable, employees |
|
— |
|
97,000 |
|
||
|
Licensed patent technology |
|
— |
|
(500,000 |
) |
||
|
Investment in joint venture (Kallikrein LLC) |
|
(1,810,000 |
) |
— |
|
||
|
Net cash used in investing activities |
|
(36,651,000 |
) |
(727,000 |
) |
||
|
|
|
|
|
|
|
||
|
Cash flows from financing activities: |
|
|
|
|
|
||
|
Proceeds from the issuance of common stock under employee stock purchase plan and exercise of stock options |
|
912,000 |
|
71,000 |
|
||
|
Net proceeds from common stock offerings |
|
44,749,000 |
|
8,261,000 |
|
||
|
Proceeds from long-term obligations |
|
— |
|
171,000 |
|
||
|
Repayment of long-term obligations |
|
(913,000 |
) |
(955,000 |
) |
||
|
Net cash provided by financing activities |
|
44,748,000 |
|
7,548,000 |
|
||
|
Effect of foreign currency translation on cash balances |
|
(23,000 |
) |
18,000 |
|
||
|
Net cash used in discontinued operations |
|
— |
|
(656,000 |
) |
||
|
|
|
|
|
|
|
||
|
Net increase in cash and cash equivalents |
|
2,891,000 |
|
2,797,000 |
|
||
|
Cash and cash equivalents at beginning of the period |
|
36,508,000 |
|
28,199,000 |
|
||
|
|
|
|
|
|
|
||
|
Cash and cash equivalents at end of the period |
|
$ |
39,399,000 |
|
$ |
30,996,000 |
|
The accompanying notes are an integral part of the unaudited consolidated financial statements.
5
DYAX CORP.
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
1. NATURE OF BUSINESS AND BASIS OF PRESENTATION
Dyax Corp. (Dyax or the Company) is a biopharmaceutical company principally focused on the discovery, development and commercialization of antibody, protein and peptide based therapeutic products. The Company currently has two product candidates in, or entering into, Phase II clinical trials for three indications. DX-88 is being studied for the treatment of both hereditary angioedema (HAE) and for the prevention of blood loss and other systemic inflammatory responses in on-pump open-heart surgery and other surgical indications, and DX-890 is being studied for the treatment of cystic fibrosis. In collaboration with Genzyme Corporation, Dyax is currently conducting an open-label, repeat dose Phase II clinical trial of DX-88 for the treatment of patients with HAE. It is a multi-center trial with investigational sites in the United States and worldwide. In April 2004, the Company treated the final patient in the dose escalating placebo-controlled study and expects to release preliminary results in June 2004. Independent of its collaboration with Genzyme, the Company has completed a Phase I/II study of DX-88 in the United States in patients undergoing coronary artery bypass grafting surgery (CABG) and plans to initiate two additional Phase II clinical trials in this indication in the second half of 2004. One, which will be conducted in Italy, will be a placebo-controlled study in high risk patients. The other will be conducted in the United States will compare DX-88 to aprotinin, currently marketed by Bayer AG under the name of Trasylol® for the reduction of blood loss in CABG patients. The Company’s collaborator for DX-890, Debiopharm S.A., has completed two Phase IIa clinical trials, one in adults and one in pediatric cystic fibrosis patients, and it intends to initiate a placebo-controlled Phase II clinical trial in this indication in the second half of 2004.
The Company uses its proprietary patented technology, known as phage display, to identify compounds with the potential for the treatment of various conditions and diseases. The Company is using phage display technology to build a broad portfolio of product candidates that it plans to develop and commercialize on its own or with others. On behalf of collaborators, the Company also uses phage display technology to identify compounds that can be used in therapeutics, diagnostic imaging, the development of research reagents, and in purifying and manufacturing biopharmaceuticals. The Company is further leveraging its phage display technology through collaborations and licenses that are structured to generate revenues through research funding, license fees, technical and clinical milestone payments, and royalties.
The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with FDA and other governmental regulations and approval requirements.
The accompanying unaudited interim consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and with the instructions to Form 10-Q. The consolidated financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated. Certain amounts from prior periods have been reclassified in the accompanying unaudited consolidated financial statements in order to be consistent with current year classifications.
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) disclosure of contingent assets and liabilities at the dates of the financial statements and (iii) the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. The results of operations for the three months ended March 31, 2004 are not necessarily indicative of the results that may be expected for the year ending December 31, 2004.
6
It is management’s opinion that the accompanying unaudited interim consolidated financial statements reflect all adjustments (which are normal and recurring) necessary for a fair presentation of the results for the interim periods. The financial statements should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2003.
2. DISCONTINUED OPERATIONS OF BIOTAGE
On October 29, 2003, the Company completed the sale of its wholly-owned subsidiary, Biotage, LLC, formerly operated as Biotage, Inc. (Biotage), to Pyrosequencing AB. The purchase price was $35.0 million before transaction expenses and deduction for approximately $4.6 million of Biotage debt. Dyax received $25.4 million in cash at closing and paid approximately $2.5 million in transaction expenses. An additional $5.0 million is being held in an indemnity escrow to cover the representations, warranties and covenants of Dyax contained in the agreement, which will be payable to Dyax within one year of the closing, to the extent that there are no valid claims against the escrow. For the three months ended March 31, 2003, operations of Biotage that were sold to Pyrosequencing are presented as discontinued operations in consolidated statements of operations and comprehensive loss and in the consolidated statements of cash flows.
The following table presents operating results for the discontinued operations of Biotage for the three months ended March 31, 2003:
|
|
|
Three
Months |
|
|
|
Separations product revenues |
|
$ |
5,419,000 |
|
|
|
|
|
|
|
|
Costs and expenses: |
|
|
|
|
|
Cost of products sold |
|
2,445,000 |
|
|
|
Research and development |
|
802,000 |
|
|
|
Selling, general and administrative |
|
2,687,000 |
|
|
|
|
|
|
|
|
|
Total costs and expenses |
|
5,934,000 |
|
|
|
|
|
|
|
|
|
Loss from operations |
|
(515,000 |
) |
|
|
|
|
|
|
|
|
Other (expense) income, net |
|
(69,000 |
) |
|
|
|
|
|
|
|
|
Loss from discontinued operations |
|
$ |
(584,000 |
) |
7
3. STOCKHOLDERS’ EQUITY
In January 2004, the Company sold 6,000,000 shares of its common stock (including 780,000 shares pursuant to the exercise by the underwriters of their over-allotment option) at a price of $7.93 per share in a registered underwritten public offering, which resulted in net proceeds to the Company of approximately $44.7 million.
Stock Options: The Company’s Amended and Restated 1995 Equity Incentive Plan (the Plan) is an equity plan under which equity awards, including awards of restricted stock and incentive and nonqualified stock options to purchase shares of common stock, may be granted to employees, directors and consultants of the Company by action of the Compensation Committee of the Board of Directors. The Company accounts for the Plan using the intrinsic value method prescribed under the recognition and measurement principles of Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees,” and related Interpretations. The following table illustrates the effect on net income and earnings per share if the Company had applied the fair value recognition provisions of Financial Accounting Standards Board (FASB) Statement No. 123, “Accounting for Stock-Based Compensation” to stock-based employee compensation. The fair value of each stock option granted is estimated under the Black-Scholes option pricing model on the grant date
|
|
|
Three
Months Ended |
|
||||
|
|
|
2004 |
|
2003 |
|
||
|
Net loss as reported |
|
$ |
(7,435,000 |
) |
$ |
(6,379,000 |
) |
|
Non-cash stock-based employee compensation included in net loss as reported |
|
40,000 |
|
140,000 |
|
||
|
Less: Total stock-based employee compensation expense determined under fair value based method for all awards |
|
(2,227,000 |
) |
(2,264,000 |
) |
||
|
Pro forma net loss |
|
$ |
(9,622,000 |
) |
$ |
(8,503,000 |
) |
|
|
|
|
|
|
|
||
|
Basic and diluted net loss per share as reported |
|
$ |
(0.24 |
) |
$ |
(0.31 |
) |
|
Pro forma basic and diluted net loss per share |
|
$ |
(0.31 |
) |
$ |
(0.42 |
) |
4. SHORT TERM INVESTMENTS
The Company considers its investment portfolio of short term investments available-for-sale as defined in FASB No. 115, “Accounting for Certain Investments in Debt and Equity Securities.” Accordingly, these investments are recorded at fair value, which is based on quoted market prices. As of March 31, 2004, the Company’s short term investments consist of obligations of U.S. government agencies with an amortized cost and estimated fair value of $34.3 million. As of March 31, 2004, an unrealized gain of $14,000 associated with these investments was recorded in other comprehensive income on the accompanying consolidated balance sheets. All short term investments mature in one year or less. The Company held no short term investments at December 31, 2003.
5. ACCOUNTS PAYABLE AND ACCRUED EXPENSES
Accounts payable and accrued expenses consist of the following:
8
|
|
|
March 31, |
|
December
31, |
|
||
|
|
|
|
|
|
|
||
|
Accounts payable |
|
$ |
4,403,000 |
|
$ |
5,426,000 |
|
|
Advance from joint venture (Kallikrein LLC) |
|
2,843,000 |
|
1,437,000 |
|
||
|
Accrued employee compensation and related taxes |
|
1,411,000 |
|
1,855,000 |
|
||
|
Accrued external research and development and contract manufacturing |
|
784,000 |
|
861,000 |
|
||
|
Other accrued liabilities |
|
1,902,000 |
|
2,750,000 |
|
||
|
|
|
$ |
11,343,000 |
|
$ |
12,329,000 |
|
6. NET LOSS PER SHARE
Net loss per share is computed under FASB Statement No. 128, “Earnings Per Share.” Basic net loss per share is computed using the weighted average number of shares of common stock outstanding. Diluted net loss per share does not differ from basic net loss per share since potential common shares from the exercise of stock options are antidilutive for all periods presented and, therefore, are excluded from the calculation of diluted net loss per share. Stock options totaling 3,420,510 and 4,193,390 were outstanding at March 31, 2004 and 2003, respectively.
7. CAPITALIZED LICENSE RIGHTS
As of March 31, 2004 and December 31, 2003, the gross carrying amount of the licensed patent technology was $3.5 million, and the related accumulated amortization was $708,000 and $583,000, respectively.
Estimated five year future amortization expense for capitalized license rights as of December 31, 2003 are as follows:
|
2004 |
|
$ |
500,000 |
|
|
2005 |
|
500,000 |
|
|
|
2006 |
|
500,000 |
|
|
|
2007 |
|
500,000 |
|
|
|
2008 |
|
500,000 |
|
|
9
8. RELATED PARTY TRANSACTIONS
Our Chief Executive Officer also serves as an outside director of Genzyme Corporation and was a consultant to Genzyme until 2001. One of our directors is a director of Genzyme and another is a senior advisor to the Chief Executive Officer of Genzyme and a former officer.
At March 31, 2004 and December 31, 2003, Genzyme owned approximately 1.8% and 2.2%, respectively of the Company’s common stock outstanding.
Investment in joint venture (Kallikrein LLC)
The Company has a collaboration agreement with Genzyme for the development and commercialization of DX-88. Under this agreement, which was amended on May 31, 2002, and again on September 30, 2003, the Company was initially responsible for all expenses incurred in connection with the development of DX-88 for the treatment of HAE through the completion of the first Phase II clinical trial for HAE, which occurred in the second quarter of 2003. In June 2003, Genzyme exercised its option to join Dyax in the formation of Kallikrein LLC, a jointly owned limited liability company, to manage the development and commercialization of DX-88. Through the formation of Kallikrein LLC, Genzyme acquired a 49.99% financial interest in the DX-88 program and is now responsible for 49.99% of all costs incurred in connection with the development of DX-88 subsequent to completion of the first Phase II clinical trial. Upon dosing the first patient in a pivotal clinical trial of DX-88 for HAE, Genzyme will also be obligated to pay the Company a milestone payment anticipated to be approximately $3.0 million. In addition, the Company will be entitled to receive potential milestone payments of $10.0 million for the first FDA approved product derived from DX-88, and up to $15.0 million for additional therapeutic indications developed under the collaboration, in addition to approximately 50% of the profits.
All research and development expenses incurred by each party related to the HAE program are billed to and reimbursed by Kallikrein LLC. The Company and Genzyme are each required to fund 50% of the forecasted monthly expenses of Kallikrein LLC on a as needed basis. The Company has accounted for its interest in the LLC using the equity method of accounting. Under this method, the reimbursement of expenses to Dyax is recorded as a reduction to research and development expenses because it includes funding that the Company provided to Kallikrein LLC. Dyax’s 50.01% share of the LLC loss is recorded as an Equity Loss in Joint Venture (Kallikrein LLC) in the consolidated statements of operations and comprehensive loss. At March 31, 2004 and December 31, 2003, the Company’s investment in the joint venture was $1.7 million and $817,000, respectively, which is recorded as an Investment in Joint Venture (Kallikrein LLC) in the consolidated balance sheets.
The Company has evaluated this agreement to determine if the related joint venture qualifies as a variable interest entity under FASB Interpretation No. 46R, “Consolidation of Variable Interest Entities” (FIN 46R) and whether or not the LLC should be consolidated. Under the scope of FIN 46R, the joint venture qualifies as a variable interest entity. The Company has a financial interest in the LLC, however it does not have a controlling interest and is not the primary beneficiary of the LLC. Accordingly, the Company has not consolidated the LLC.
Under the collaboration agreement, as amended, the Company had the option to purchase Genzyme’s interest in the application of DX-88 for the prevention of blood loss and other systemic inflammatory responses in on-pump open-heart surgery and other surgical indications for $1.0 million. The Company exercised this option in the first quarter of 2003.
10
When the Company and Genzyme first amended the collaboration agreement in May 2002, the Company and Genzyme also executed a senior secured promissory note and security agreement under which Genzyme agreed to loan the Company up to $7.0 million and the Company agreed to grant Genzyme a continuing security interest in certain tangible and intangible personal property arising out of the DX-88 program. In addition, under the terms of the security agreement, once the Company exercised its option to purchase Genzyme’s interest in the application of DX-88 in on-pump open-heart surgery and other surgical indications, the Company was required to pledge to Genzyme a percentage interest in its wholly-owned subsidiary, Biotage. Under an amendment to the security agreement executed on October 15, 2003, Genzyme agreed to release the interest in Biotage pledged to it in exchange for a continuing security interest in the Company’s rights to revenues from licenses of its fundamental phage display patent portfolio. The security agreement, as amended, contains certain financial covenants, under which the Company must maintain at least $20.0 million in cash or cash equivalents based on the Company’s quarterly consolidated financial statements and that the Company maintains its listing standard for the Nasdaq National Market.
On October 18, 2002, the Company received the $7.0 million under this Genzyme note. The note bears interest at the prime rate (4.0% at March 31, 2004) plus 2%. Interest is payable quarterly. The principal and all unpaid interest will be due on the maturity date of May 31, 2005. The Company may extend the maturity date to May 31, 2007 if the Amended Collaboration Agreement is in effect, no default or event of default exists and the Company satisfies the financial covenants as of the initial maturity date. As of March 31, 2004 and December 31, 2003, there was $7.0 million outstanding under the loan, which is presented as an obligation to related party on the Company’s consolidated balance sheets. At March 31, 2004 and December 31, 2003, the Company owed $104,000 and $488,000, respectively, of interest on this note, which is included in accounts payable and accrued expenses due to the current nature of this liability.
9. LITIGATION
The Company’s first phage display patent in Europe, European Patent No. 436,597, known as the 597 Patent was ultimately revoked in 2002 in a proceeding in the European Patent Office. The Company has two divisional patent applications of the 597 Patent pending in the European Patent Office. The Company will not be able to prevent other parties from using its phage display technology in Europe if the European Patent Office does not grant the Company another patent. The Company cannot be assured that it will prevail in the prosecution of either of these patent applications.
George Pieczenik and I.C. Technologies America, Inc. sued the Company in 1999 for patent infringement of three United States patents. The complaint was initially filed against the Company in New York, dismissed for lack of jurisdiction and then refiled in the United States District Court in Massachusetts. On February 25, 2003, the District Court granted summary judgment of noninfringement in the Company’s favor with respect to the three asserted patents. On March 5, 2003, the plaintiff filed a Notice of Appeal to the United States Court of Appeals for the Federal Circuit (CAFC). On September 23, 2003 the CAFC affirmed the decision of the United States District Court granting summary judgment that the Company does not infringe the patents asserted by the plaintiff. The plaintiff has filed a petition for certiorari with the United States Supreme Court for the review of the decision by the CAFC. On March 29, 2004, the United States Supreme Court denied the petition. On December 21, 2003, the plaintiff asked the District Court to reconsider its decision that the Company did not infringe plaintiff’s patents. The Massachusetts Court denied plaintiff’s request on January 7, 2004. On January 19, 2004, plaintiff appealed that decision to the CAFC.
George Pieczenik also filed an action in the United States District Court for the Southern District of New York, alleging, among other things, that the Company (and each of several other defendants) infringes a newly issued patent, which issued on August 12, 2003. The Company challenged the new lawsuit on several grounds (including jurisdictional and venue grounds) and on October 9, 2003 the District Court dismissed the action as to the Company. The Court subsequently dismissed the action as to one of the
11
Company’s directors and one of its former officers. As a result, Dyax, its directors and officers are no longer parties to the New York Court action.
As of March 31, 2004, we were not engaged in any active court proceedings, although possible appeals are pending in the Pieczenik litigation. We make provisions for claims specifically identified for which we believe the likelihood of an unfavorable outcome is probable and reasonably estimable. We record at least the minimum estimated liability related to claims where there is a range of loss and the loss is considered probable. Because of the uncertainties related to the likelihood and amount of loss on any of our pending claims, we are unable to make a reasonable estimate of the liability that could result from an unfavorable outcome of those claims. As additional information becomes available, we assess the potential liability related to our pending claims and revise our estimates. Future revisions in our estimates of the potential liability could materially impact our results of operations and financial position. We maintain insurance coverage that limits the exposure for any single claim as well as total amounts incurred per policy year, and we believe our insurance coverage is adequate. We make every effort to use the best information available to us in determining the level of liability reserves. As of March 31, 2004, we have no reserves for litigation settlements. The Company does not expect the outcome of any of the above matters to have a material impact on its financial position or results of operations.
10. BUSINESS SEGMENTS
The Company discloses business segments under SFAS 131, “Disclosures about Segments of an Enterprise and Related Information,” which established standards for reporting information about operating segments in annual financial statements of public business enterprises. It also establishes standards for related disclosures about products and service, geographic areas and major customers. On October 29, 2003, the Company sold its separations products business known as Biotage, which was previously disclosed as the Separations segment. The Company has reevaluated its business activities that are regularly reviewed by the Chief Executive Officer for which discrete financial information is available. As a result of this evaluation, the Company determined that it has one segment with operations in two geographic locations. As of March 31, 2004 and December 31, 2003, the Company had approximately $2.0 and $1.9 million of long-lived assets located in Europe, with the remainder held in the United States. For the three months ended March 31, 2004 and 2003, the Company did not have any external revenues outside the United States.
Item 2 - - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The discussion in this item and elsewhere in this report contains forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. These risks and uncertainties include those described under “Important Factors That May Affect Future Operations and Results” below.
OVERVIEW
We are a biopharmaceutical company principally focused on the discovery, development and commercialization of antibody, protein and peptide based therapeutic products. We currently have two product candidates in or entering into Phase II clinical trials for three indications. DX-88 is being studied for the treatment of both hereditary angioedema (HAE) and for the prevention of blood loss and other systemic inflammatory responses in on-pump open-heart surgery and other surgical indications, and DX-890 is being studied for the treatment of cystic fibrosis.
We use our proprietary, patented technology, known as phage display, to identify a range of compounds consisting of monoclonal antibodies, small proteins and peptides, with the potential for the treatment of various diseases. We are using phage display technology to build a broad portfolio of product candidates that we plan to develop and commercialize either ourselves or with others. On behalf of
12
collaborators, we also use phage display technology to identify compounds that can be used in therapeutics, diagnostic imaging agents and to purify biopharmaceuticals. We are further leveraging our phage display technology through collaborations and licenses that are structured to generate revenues through research funding, license fees, technical and clinical milestone payments, and royalties.
On October 29, 2003, we completed the sale of our wholly-owned separations product subsidiary Biotage, LLC, formerly operated as Biotage, Inc. (Biotage), to Pyrosequencing AB. The sale of Biotage has allowed us to focus exclusively on biotherapeutics, and the cash generated by the sale of Biotage will help us advance our clinical programs as well as the pre-clinical candidates in our pipeline. The purchase price was $35.0 million before transaction expenses and deduction for approximately $4.6 million of Biotage debt. We received approximately $25.4 million in cash at closing and paid approximately $2.5 million in transaction expenses. An additional $5.0 million is being held in an indemnity escrow to cover the representations, warranties and covenants of Dyax contained in the agreement, of which $1.5 million was paid to us on April 29, 2004 and the remaining $3.5 million will be payable to us within one year to the extent that there are no valid claims against the escrow. As of May 5, 2004, there have been no claims made against the escrow. The operations of Biotage for the period ended March 31, 2003 are presented as discontinued operations in the consolidated statements of operations and comprehensive loss, and the statements of cash flows.
We continued to incur losses in the first quarter of 2004 and expect to incur significant operating losses over at least the next several years as we continue our current and anticipated development projects, particularly our clinical trial programs for DX-88 and DX-890, and as we develop our discovery, research, marketing, sales and manufacturing capabilities.
Clinical Development Programs
DX-88 for HAE. In collaboration with Genzyme, we are currently developing DX-88 as a treatment for HAE in an open-label, repeat dose Phase II clinical trial known as EDEMA2. EDEMA2 is a multi-center trial with investigational sites in the US and worldwide. In March 2003, we successfully completed patient treatment in a nine-patient Phase II, dose ranging clinical trial in Europe. In April 2004, we treated the final patient in the EDEMA1 study, a dose escalating placebo-controlled study and expect to release preliminary results in June 2004.
The following table illustrates the activity associated with DX-88 for HAE included in our consolidated statements of operations and comprehensive loss:
|
|
|
Three Months Ended March 31, |
|
||||
|
|
|
2004 |
|
2003 |
|
||
|
DX-88 for HAE costs included within research and development expenses in the consolidated statements of operations and comprehensive loss |
|
$ |
1,510,000 |
|
$ |
966,000 |
|
|
Less research and development expenses reimbursed by joint venture (Kallikrein LLC) per the consolidated statements of operations and comprehensive loss |
|
(1,510,000 |
) |
— |
|
||
|
Net research and development expenses for DX-88 for HAE |
|
— |
|
966,000 |
|
||
|
Equity loss in joint venture (Kallikrein LLC) separately classified within the consolidated statements of operations and comprehensive loss |
|
882,000 |
|
— |
|
||
|
Net loss on DX-88 for HAE program |
|
$ |
882,000 |
|
$ |
966,000 |
|
During the three months ended March 31, 2004 (the 2004 Quarter), research and development expenses on this program totaled $1.5 million compared with $966,000 in the three months ended March
13
31, 2003 (the 2003 Quarter). This increase was principally due to increased activity in the areas of manufacturing and quality to support our ongoing clinical trials. During the 2004 Quarter Kallikrein LLC fully reimbursed us for our costs incurred on this program. This reimbursement is recorded as research and development expenses reimbursed by joint venture (Kallikrein LLC) in our consolidated statements of operations and comprehensive loss because it includes funding we provided to Kallikrein LLC.
Kallikrein LLC had a net loss of approximately $1.8 million, for the 2004 Quarter. This loss represents the total research and development expenses incurred by Dyax and Genzyme on DX-88 for HAE. Our portion of the loss, accounted for under the equity method, of $882,000 is our 50.01% financial interest in the program and is separately classified within the consolidated statements of operations and comprehensive loss.
We currently anticipate filing a Biologic License Application (BLA) for DX-88 for the treatment of HAE in 2005. Based upon this timeline, we estimate Kallikrein LLC’s total remaining costs to commercialization to be in the range of $50 million to $58 million. We will be responsible for funding one half of these costs, or $25 million to $29 million. These costs exclude costs associated with the development of an alternative method for delivering the drug.
DX-88 for CABG. Independent of our collaboration with Genzyme, we are developing DX-88 as a treatment for patients undergoing on-pump open-heart surgery, specifically coronary artery bypass graft surgery (CABG). During the first quarter of 2003, we exercised an option to purchase from Genzyme full rights to DX-88 for this and other surgical indications. The cost for exercising the option was $1.0 million and was expensed in the 2003 Quarter.
During the 2004 Quarter, research and development expenses on this program totaled $552,000 million compared with $1.2 million for the 2003 Quarter. The decrease in spending is attributable to the $1.0 million option exercise price paid to Genzyme in the 2003 Quarter, partially offset by a $280,000 increase in clinical research costs. We plan to initiate two additional Phase II clinical trials in this indication in the second half of 2004. One, which will be conducted in Italy will be a placebo-controlled study in high risk patients. The other will be conducted in the United States and will compare DX-88 to aprotinin, currently marketed by Bayer AG under the name of Trasylol® for reduction of blood loss in CABG patients. We expect these trials to cost approximately $4.5 to $5.5 million. The trial to be conducted in the United States is currently planned to involve approximately 100 patients and may be expanded to a full Phase III clinical trial following an interim analysis of the data. The expanded trial could involve approximately 1,000 patients and would entail significant additional costs. Before we proceed with any Phase III clinical trial, we plan to partner with another company or obtain additional financing that will allow us to develop the product independently.
DX-890 for Cystic Fibrosis. In collaboration with Debiopharm S.A., DX-890 is being developed as a treatment for cystic fibrosis. Debiopharm has completed two Phase IIa clinical trials with DX-890 in Europe, one in adult and one in pediatric cystic fibrosis patients, and is planning to initiate a placebo-controlled Phase II clinical trial for cystic fibrosis in the second half of 2004. In addition, we are currently considering alternatives to accelerate the clinical development of DX-890, including conducting independent clinical trials in the United States and elsewhere.
During the 2004 Quarter, we incurred research, development and manufacturing expenses on this program of $3.0 million compared with $221,000 in the 2003 Quarter. Research and development expenses on this program increased from the 2003 Quarter to the 2004 Quarter principally due to an increase in manufacturing costs resulting from the timing of cost recognition. These costs were fully funded by Debiopharm and are reflected in our product development revenues. Under our existing collaboration agreement, Debiopharm is responsible for the management of all non-clinical and clinical trials, all costs associated with such clinical trials and any costs incurred by Dyax in connection with the manufacture and testing of the active pharmaceutical ingredient for DX-890 are fully funded by Debiopharm. This financial structure could be altered if we were to amend our collaboration agreement with Debiopharm and assume responsibility for the clinical development of DX-890.
14
Goals for Clinical Development Programs. Our goal for each of our three ongoing clinical development programs is to obtain marketing approval from the FDA and analogous international regulatory agencies. Because of uncertainties associated with our ongoing clinical trials, our ability to locate a development partner or obtain the additional funding needed to complete clinical trials in the CABG and cystic fibrosis programs, the preparation and filing of a BLA, the regulatory review process, and the risks associated with the clinical approval process, including the risk that we may have to repeat, revise or expand the scope of trials or conduct additional clinical trials not presently planned to secure marketing approvals, we are unable to accurately predict the costs to complete any of these programs, the completion dates, or whether these projects will be successfully completed at all. Material cash inflows for any of these programs will not commence until after marketing approvals are obtained, and then only if the product candidate finds acceptance in the marketplace as a treatment for its disease indication. Because of the many risks and uncertainties relating to the completion of clinical trials, receipt of marketing approvals and acceptance in the marketplace, we cannot predict when material cash inflows from these programs will commence, if ever.
Discovery Programs
Through internal discovery activities and through business relationships with academic institutions and private genomics companies, we use our proprietary phage display technology to identify compounds with therapeutic potential. We have eleven discovery programs underway as described in our Annual Report on Form 10-K for 2003.
Licensing and Funded Research Activities
We have granted over 75 companies and institutions licenses to use our proprietary phage display technology and phage display libraries. These licenses allow others to exploit our technology in therapeutic discovery and in non-core areas such as diagnostic imaging, research reagents and separations. In addition, we perform funded research for collaborators within the biopharmaceutical industry. We believe that these programs provide support for our patent position in phage display and for the usefulness of phage display as an enabling discovery technology. Additionally, these programs generate short term and long term value for us through licensing fees, milestones and royalties.
RESULTS OF OPERATIONS
THREE MONTHS ENDED MARCH 31, 2004 AND 2003
Revenue. Substantially all our revenues have come from licensing, funded research and development activities, including milestone payments from our licensees and collaborators. These revenues fluctuate from quarter to quarter. Revenues increased to $5.7 million in the 2004 Quarter from $3.9 million in the 2003 Quarter, an increase of $1.8 million or 48%. This increase was primarily due to a $3.1 million quarter-to-quarter increase in revenue arising from our DX-890 product collaboration with Debiopharm. On a quarter-to-quarter basis our DX-890 manufacturing revenue may vary substantially due to the timing of production activities. This increase was partially offset by the recognition of $1.0 million in the 2003 Quarter under a funded research agreement with Human Genome Sciences, Inc., which was completed in June 2003.
Net Research and Development. Our research and development expenses arise primarily from compensation and other related costs, including personnel dedicated to research and development activities and from the fees paid and costs reimbursed to outside professionals to conduct research, clinical studies and trials, and to manufacture drug compounds and related supplies prior to FDA approval. Our net research and development expenses for the 2004 Quarter were $8.8 million, compared with $6.7 million for the 2003 Quarter. The increase was primarily due to the recognition of $2.3 million of reimbursable manufacturing expenses under our DX-890 product collaboration. The increase was partially offset by the
15
reimbursement by Kallikrein LLC of $1.5 million of our costs associated with the development of DX-88 for the treatment of HAE. All development expenses incurred by the related parties on behalf of Kallikrein LLC are billed to and reimbursed by Kallikrein LLC. Because the reimbursement we received includes funding that we provided to the LLC, we recorded the reimbursement as a reduction of research and development expenses so that we present net research and development expenses in our consolidated statements of operations and comprehensive loss. The 2003 Quarter’s research and development expenses also reflect the cost of exercising a $1.0 million option to purchase the rights to DX-88 for on-pump open-heart surgery and other surgical indications from Genzyme.
Equity Loss in Joint Venture (Kallikrein LLC). The consolidated statement of operations and comprehensive loss also reflects our equity loss in joint venture (Kallikrein LLC) of $882,000 in the 2004 Quarter. This loss represents the Company’s pro rata share of Kallikrein LLC’s net loss.
General and Administrative. Our general and administrative expenses consist primarily of the costs of our management and administrative staff, as well as expenses related to business development, protecting our intellectual property, administrative occupancy, professional fees, market research and promotion activities and the reporting requirements of a public company. General and administrative expenses increased to $3.3 million for the 2004 Quarter compared to $2.7 million for the 2003 Quarter, an increase of $543,000. The increase was primarily due to a $258,000 increases in premarketing activities relating to our compounds in clinical trials and incremental increases in employee and occupancy costs.
Discontinued Operations. Our activities from discontinued operations of $584,000 are the operations of Biotage, which were sold to Pyrosequencing on October 29, 2003.
LIQUIDITY AND CAPITAL RESOURCES
We require cash to fund our operating expenses, to make capital expenditures, acquisitions and investments, and to pay debt service. Through March 31, 2004, we have funded our operations principally through the sale of equity securities, which have provided aggregate net cash proceeds since inception of approximately $187.2 million, including net proceeds of $44.7 from our January 2004 registered underwritten public offering, $8.3 million from our March 2003 registered directed offering and $62.4 million from our August 2000 initial public offering. We have also generated funds from biopharmaceutical product development and license fee revenues, the sale of our Biotage subsidiary in 2003, separations product revenues of our former Biotage division, interest income, long term obligations and other sources. As of March 31, 2004, we had cash and cash equivalents and short term investments aggregating $73.7 million. Our excess funds are currently invested in short term investments primarily consisting of obligations of U.S. government agencies and money market funds backed by U.S. Treasury obligations.
Our operating activities used cash of $5.2 million in the 2004 Quarter, compared with $3.4 million in the 2003 Quarter. Our cash used in operating activities for the 2004 Quarter consisted primarily of our net loss of $7.4 million, a decrease in deferred revenue of $1.6 million due primarily to the timing of revenue recognition on our collaboration with Debiopharm, and a decrease in accounts payable and accrued expenses of $957,000, partially offset by a decrease in accounts receivable of $2.4 million due to the timing and collection of billings, a $882,000 equity loss in joint venture (Kallikrein LLC) and depreciation and amortization costs totaling $781,000. Our cash used in operating activities for the 2003 Quarter consisted primarily of our net loss of $5.8 million partially offset by the $1.1 provided by the change in accounts payable and accrued expenses relating timing differences between incurring a liability and payment, and depreciation and amortization costs totaling $769,000.
Our investing activities used cash of $36.7 million in the 2004 Quarter, compared with $727,000 in the 2003 Quarter. Our investing activities for the 2004 Quarter included the purchase of mortgage securities and obligations of U.S. government agencies and related accrued interest receivable totaling
16
$34.5 million with a portion of the proceeds from our January common stock offering and $1.8 million paid to Kallikrein LLC. The investing activities for the 2003 Quarter included the payment of $500,000 for patent technology, the purchase of fixed assets totaling $177,000 and a $147,000 increase in restricted cash.
The following table summarizes our cash contribution to and investment in our joint venture, Kallikrein LLC.
|
|
|
Three
Months Ended |
|
|
|
|
|
|
|
|
|
Balance at beginning of period |
|
$ |
817,000 |
|
|
Investment in joint venture (Kallikrein LLC) per the consolidated statement of cash flows |
|
1,810,000 |
|
|
|
Equity loss in joint venture (Kallikrein LLC) separately classified within the consolidated statements of operations and comprehensive loss |
|
(882,000 |
) |
|
|
|
|
|
|
|
|
Balance at end of period |
|
$ |
1,745,000 |
|
Our financing activities provided cash of $44.7 million in the 2004 Quarter, compared with $7.5 million in the 2003 Quarter. Our financing activities for the 2004 Quarter included net proceeds of $44.7 million from our January 2004 common stock offering and $912,000 from the issuance of common stock under our employee stock purchase plan and exercise of stock options. These proceeds were partly offset by repayments of long-term obligations of $913,000. Our financing activities for the 2003 Quarter included net proceeds $8.3 million from our March 2003 registered directed offering. These proceeds were partially offset by $955,000 in repayments of long-term obligations.
We have financed fixed asset acquisitions through capital leases and debt. Capital lease obligations are collateralized by the assets under lease. Certain debt obligations, as amended, are collateralized by a stand-by letter of credit for the amount financed, of which none is outstanding at March 31, 2004. As of March 31, 2004, these debt obligations totaled $811,000 and will be fully paid by December 31, 2004.
In conjunction with our collaboration agreement with Genzyme for the development of DX-88, Genzyme agreed to loan us up to $7.0 million pursuant to a senior secured promissory note and security agreement, and we agreed to grant Genzyme a continuing security interest in certain tangible and intangible personal property arising out of the DX-88 program. In addition, the security agreement, as amended contains certain financial covenants under which we must maintain at least $20.0 million in cash or cash equivalents based on our quarterly consolidated financial statements and maintain at least one continued listing standard for the Nasdaq National Market. As of March 31, 2004, we had borrowed the full $7.0 million available under the note, the terms of which are discussed in Note 8 to the consolidated financial statements.
Statements about our expectations of the period of time through which financial resources will be adequate to support our operations are forward-looking statements that involve risks and uncertainties. Actual results could vary as a result of a number of factors. We believe that existing cash and cash equivalents and short term investments plus anticipated cash flow from product development, license fees and collaborations will be sufficient to support our current operating plans into 2006. Exclusive of net proceeds of $44.7 million from our January 2004 common stock offering, we expect to use approximately $25 million in cash during 2004, net of the anticipated release of the $5.0 million escrow from the sale of Biotage. If our existing resources and cash flows from product development and license fees are insufficient to satisfy our liquidity requirements or if market conditions are favorable, we may choose to sell additional equity or debt securities. The sale of any equity or debt securities may result in additional
17
dilution to our stockholders, and we cannot be certain that additional financing will be available in amounts or on terms acceptable to us, if at all. If we are unable to obtain any required additional financing, we may be required to reduce the scope of our planned research, development and commercialization activities, which could harm our financial condition and operating results.
We have no off-balance sheet arrangements with the exception of operating leases.
COMMITMENTS AND CONTINGENCIES
In our Form 10-K for the year ended December 31, 2003 under the heading “Contractual Obligations,” we outlined our commitments and contingencies. For the quarter ended March 31, 2004, there have been no material changes in our commitments and contingencies, except for those disclosed in the notes to the unaudited consolidated financial statements (see Notes 8 and 9).
CRITICAL ACCOUNTING ESTIMATES
In our Form 10-K for the year ended December 31, 2003, our most critical accounting policies and estimates upon which our financial status depends upon were identified as those relating to revenue recognition, allowance for doubtful accounts and valuation of long-lived and intangible assets. We reviewed our policies and determined that those policies remain our most critical accounting policies for the quarter ended March 31, 2004. We did not make any changes in those policies during the quarter ended March 31, 2004.
IMPORTANT FACTORS THAT MAY AFFECT FUTURE OPERATIONS AND RESULTS
This Quarterly Report on Form 10-Q contains forward-looking statements. These forward-looking statements appear principally in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements may appear in other sections of this report as well. Generally, the forward-looking statements in this report use words like “expect,” “believe,” “continue,” “anticipate,” “estimate,” “may,” “will,” “could,” “opportunity,” “future,” “project,” and similar expressions.
The forward-looking statements include statements about our:
• expected future revenues, operations and expenditures;
• research and development programs;
• results of clinical trials and projected timetables for the preclinical and clinical development of, regulatory submissions and approvals for, and market introduction of, our product candidates;
• income tax benefits;
• projected cash needs;
• assessments of competitors and potential competitors;
• credit facilities; and
• collaborations.
18
Statements that are not historical facts are based on our current expectations, beliefs, assumptions, estimates, forecasts and projections for our business and the industry and markets in which we compete. The forward-looking statements contained in this report are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. We caution investors not to place undue reliance on the forward-looking statements contained in this report. These statements speak only as of the date of this report, and we do not undertake any obligation to update or revise them, except as required by law.
The following factors, among others, create risks and uncertainties that could affect our future or other performance:
• our history of operating losses and our expectation that we will incur significant additional operating losses;
• any inability to raise the capital that we will need to sustain our operations;
• any inability to successfully and expeditiously complete the rigorous clinical trials and regulatory approvals processes that any biopharmaceutical product candidates that we develop must undergo, which could substantially delay or prevent their development or marketing;
• our dependence on third parties to manufacture biopharmaceuticals, which may adversely affect our ability to commercialize any biopharmaceuticals we may develop;
• our lack of experience in conducting clinical trials, regulatory processes, and sales and marketing activities, any or all of which may adversely impact our ability to commercialize any biopharmaceuticals we may develop;
• our dependence on our collaborator to successfully and timely complete clinical trials for our DX-890 product candidate;
• any inability to establish and maintain successful license and collaborative relationships could adversely affect our ability to generate revenues;
• any failure by us or our collaborators to gain market acceptance of biopharmaceuticals we own or develop;
• competition and technological change that may make our product candidates and technologies less attractive or obsolete;
• any inability to obtain and maintain intellectual property protection for our product candidates and technologies;
• time consuming and expensive proceedings to obtain, enforce or defend patents and to defend against charges of infringement that may result in unfavorable outcomes and could limit our patent rights and our activities;
• the scope, validity and enforceability of patents and other proprietary rights held by third parties and their impact on our ability to commercialize our product candidates and technology;
19
• significant fluctuations in our revenues and operating results, which have occurred in the past and which we expect to continue to fluctuate in the future;
• any loss or inability to hire and retain qualified personnel;
• our handling, storage or disposal of hazardous materials used and generated in our business may be time-consuming and expensive;
• our exposure to product liability;
• risks associated with international operations and collaborations;
• any inability to obtain continued funding of clinical development product candidates by our development partners;
• our common stock may continue to have a volatile public trading price and low trading volume; and
• anti-takeover provisions in our governing documents and under Delaware law and our shareholder rights plan that may make an acquisition of us more difficult.
As a result of the foregoing and other factors, we may experience material fluctuations in our future operating results, which could materially affect our business, financial position, and stock price. These risks and uncertainties are discussed in more detail in Exhibit 99.1 “Important Factors That May Affect Future Operations and Results” filed with our annual report on Form 10-K, for the year ended December 31, 2003.
Item 3 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Our exposure to market risk consists primarily of our cash and cash equivalents, short term investments, long-term obligations and forward contracts for the purchase of foreign currency. We place our investments in high-quality financial instruments, primarily obligations of U.S. government agencies and money market funds backed by U.S. Treasury obligations, which we believe are subject to limited credit risk. We currently do not hedge interest rate exposure. As of March 31, 2004, we had cash and cash equivalents of approximately $39.4 million primarily consisting of money market funds backed by U.S. Treasury obligations and short-term investments totaling $34.3 million consisting of investments in obligations of U.S. government agencies that mature over the next year. Our short-term investments will decline by an immaterial amount if market interest rates increase by 10%, and therefore, our exposure to interest rate changes is immaterial. Declines of interest rates over time will, however, reduce our interest income from our short-term investments.
As of March 31, 2004, we had $13.4 million outstanding under long-term obligations. Interest rates on $6.4 million of these obligations are fixed and therefore are not subject to interest rate fluctuations. Interest on the $7.0 million Genzyme note is variable based on the prime interest rate and is therefore subject to interest rate fluctuations. A 2% increase in the prime rate will result in an additional $140,000 in annual interest expense.
Most of our transactions are conducted in U.S. dollars. We have collaboration and technology license agreements and a research subsidiary located outside the United States. Transactions under certain of these agreements and by our subsidiary are conducted in local foreign currencies. To help reduce our risk to changes in the foreign currency market, we have entered into some short term forward contracts. If exchange rates undergo a change of up to 10%, we will have to record a loss or gain on foreign currency of approximately $200,000.
20
Item 4 - CONTROLS AND PROCEDURES
(a) Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, the “Exchange Act”) as of the end of the period covered by this quarterly report. Based on this evaluation, our principal executive officer and principal financial officer concluded that these disclosure controls and procedures are effective and designed to ensure that the information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the requisite time periods.
(b) Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) identified in connection with the evaluation of our internal control that occurred during our fiscal quarter ended March 31, 2004 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Item 6 – EXHIBITS AND REPORTS ON FORM 8-K
(a) - - Exhibits
|
EXHIBIT |
|
DESCRIPTION |
|
|
|
|
|
3.1 |
|
Restated Certificate of Incorporation of the Company. Filed as Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q (File No. 000-24537) for the quarter ended September 30, 2000 and incorporated herein by reference. |
|
|
|
|
|
3.2 |
|
Amended and Restated By-laws of the Company. Filed as Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q (File No. 000-24537) for the quarter ended September 30, 2000 and incorporated herein by reference. |
|
|
|
|
|
3.3 |
|
Certificate of Designations Designating the Series A Junior Participating Preferred Stock of the Company. Filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 000-24537) and incorporated herein by reference. |
|
|
|
|
|
3.4 |
|
Certificate of Correction to the Restated Certificate of Incorporation of the Company. Filed as Exhibit 3.4 to the Company’s Amendment No. 1 to the Annual Report on Form 10-K/A (File No. 000-24537) and incorporated herein by reference. |
|
|
|
|
|
10.1 |
|
Employment Letter Agreement, dated August 23, 2001, between Anthony H. Williams, M.D. and the Company. Filed herewith. |
|
|
|
|
|
10.2 |
|
Employment Letter Agreement, dated August 28, 2001, between Lynn G. Baird, Ph.D. and the Company. Filed herewith. |
21
|
10.3 |
|
Employment Letter Agreement, dated June 27, 2003, between Clive R. Wood, Ph.D. and the Company. Filed herewith. |
|
|
|
|
|
31.1 |
|
Certification of Chief Executive Officer Pursuant to §240.13a-14 or §240.15d-14 of the Securities Exchange Act of 1934, as amended. Filed herewith. |
|
|
|
|
|
31.2 |
|
Certification of Chief Financial Officer Pursuant to §240.13a-14 or §240.15d-14 of the Securities Exchange Act of 1934, as amended. Filed herewith. |
|
|
|
|
|
32 |
|
Certification pursuant to 18 U.S.C. Section 1350. Filed herewith. |
(b) Reports on Form 8-K
We filed a Current Report on Form 8-K on February 18, 2004, in order to furnish to the Securities and Exchange Commission a press release issued by us announcing our financial results for the quarter and year ended December 31, 2003.
22
DYAX CORP.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
DYAX CORP. |
|
|
|
|
|
|
Date: May 6, 2004 |
|
|
|
|
/s/ Stephen S. Galliker |
|
|
|
Executive
Vice President, Finance |
|
23
DYAX CORP.
|
EXHIBIT |
|
DESCRIPTION |
|
|
|
|
|
3.1 |
|
Restated Certificate of Incorporation of the Company. Filed as Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q (File No. 000-24537) for the quarter ended September 30, 2000 and incorporated herein by reference. |
|
|
|
|
|
3.2 |
|
Amended and Restated By-laws of the Company. Filed as Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q (File No. 000-24537) for the quarter ended September 30, 2000 and incorporated herein by reference. |
|
|
|
|
|
3.3 |
|
Certificate of Designations Designating the Series A Junior Participating Preferred Stock of the Company. Filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 000-24537) and incorporated herein by reference. |
|
|
|
|
|
3.4 |
|
Certificate of Correction to the Restated Certificate of Incorporation of the Company. Filed as Exhibit 3.4 to the Company’s Amendment No. 1 to the Annual Report on Form 10-K/A (File No. 000-24537) and incorporated herein by reference. |
|
|
|
|
|
10.1 |
|
Employment Letter Agreement, dated August 23, 2001, between Anthony H. Williams, M.D. and the Company. Filed herewith. |
|
|
|
|
|
10.2 |
|
Employment Letter Agreement, dated August 28, 2001, between Lynn G. Baird, Ph.D. and the Company. Filed herewith. |
|
|
|
|
|
10.3 |
|
Employment Letter Agreement, dated June 27,2003, between Clive R. Wood, Ph.D. and the Company. Filed herewith. |
|
|
|
|
|
31.1 |
|
Certification of Chief Executive Officer Pursuant to §240.13a-14 or §240.15d-14 of the Securities Exchange Act of 1934, as amended. Filed herewith. |
|
|
|
|
|
31.2 |
|
Certification of Chief Financial Officer Pursuant to §240.13a-14 or §240.15d-14 of the Securities Exchange Act of 1934, as amended. Filed herewith. |
|
|
|
|
|
32 |
|
Certification pursuant to 18 U.S.C. Section 1350. Filed herewith. |
24